Stock Detail
AFFYMETRIX INC
Sector: Biotechnology
Latest Quote @ Fri May 5 13:32:53 (15 min delayed)
| $3.68 |
$3.69 |
$3.69 |
+0.01 |
0.27% |
|
Last Day's Data
| $3.68 |
$3.72 |
$0.01 |
0.27% |
0.00 |
$3.67 |
| $3.63 |
$3.53 |
252,783.00 |
261.64M |
655,203.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 3.83 |
3.75 |
3.64 |
3.56 |
3.45 |
Stock Profile
Affymetrix, Inc. engages in the development, manufacture, sale, and service of systems for genetic analysis for use in the life sciences and in clinical diagnostics. The company's GeneChip system consists of components, including disposable probe arrays containing genetic information on a chip, reagents for extracting, amplifying, and labeling target nucleic acids, a fluidics station for introducing the test sample to the probe arrays, a hybridization oven for optimizing the binding of samples to the probe arrays, a scanner to read the fluorescent image from the probe arrays, and software to analyze and manage the resulting genetic information. The company also offers related microarray technology, which includes instrumentation, software, and licenses for fabricating, scanning, collecting, and analyzing results from low density microarrays. It sells its products to pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies, as well as academic research centers, government research laboratories, private foundation laboratories, and clinical reference laboratories in North America and Europe. Affymetrix has an agreement with The Jeffrey Modell Foundation and National Human Genome Research Institute to develop two molecular DNA tests that could help save the lives of children born with severe combined immunodeficiency and other primary immunodeficiency disorders; a collaboration with CureSearch Children's Oncology Group to discover and validate gene expression signatures, or genetic fingerprints, for various common childhood cancers, including leukemia and sarcoma, a common solid tumor; and a collaboration with Imperial College London and the Medical Research Council to discover the genetic variations associated with cancer, cardiovascular disease, and diabetes. The company was founded in 1991 and is headquartered in Santa Clara, California.
